GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer

NCT05575804 | Recruiting Phase 1

• 1 other identifier: GRACE
• Study Type: interventional
• Target: 32
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this trial is to study the safety, pharmacokinetics and preliminary efficacy of the HER2-targeted antibody-drug conjugate GQ1001 in combination with pyrotinib in patients with HER2-positive metastatic breast cancer patients who had failed previous anti-HER2 treatment.

Conditions

Advanced/ Metastatic Her-2 Positive Breast Cancer

Keywords

HER2-ADC; pyrotinib; Advanced/ Metastatic Her-2 positive Breast Cancer

Outcome Measures

Primary Outcomes (4)

• Dose-limiting toxicities (DLTs), Phase I

  Side effects of drug or treatment that are serious enough to prevent an increase in dose or level of that treatment, according to NCI-CTCAE Version 5.0.

  From the first dose to the end of Cycle 1, 21 days

• Maximum Tolerated Dose (MTD), Phase I

  Highest administered dose with \< 33% of participants experiencing dose-limiting toxicity (DLT) in the first 6 DLT evaluable participants.

  From the first dose to the end of Cycle 1, 21 days

• Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

  Incidence and severity of Treatment-emergent adverse events, treatment-related adverse events and serious adverse events, according to NCI-CTCAE Version 5.0 (The number of participants who had treatment-related side effects in the population who had received one therapy at least).

  up to 24 months

• Objective Response Rate (ORR), Confirmed by the researcher's evaluation, Phase II

  The objective response rate will be analyzed according to the RECIST 1.1 standard tumor evaluation.

  up to 24 months

Secondary Outcomes (7)

• Maximum Serum Concentration (Cmax), Phase I

  At the end of Cycle 3 (each cycle is 21 days)

• Trough Serum concentration (Cthough), Phase I

  At the end of Cycle 3 (each cycle is 21 days)

• Area Under the Concentration-time Curve (AUC), Phase I

  At the end of Cycle 3 (each cycle is 21 days)

• Objective Response Rate (ORR), Phase I

  up to 24 months

• Duration of Response (DoR)

  up to 24 months

Study Arms (1)

experimental group

EXPERIMENTAL

Patients will receive the recommended phase II dose of GQ1001 determined in phase I. GQ1001 infusions on day 1 of each 21-day cycle combinate with pyrotinib 320mg orally once daily until disease progression or unacceptable toxicity.

Drug: GQ1001+pyrotinib

Interventions

GQ1001+pyrotinib DRUG

GQ1001 infusions on day 1 of each 21-day cycle combinate with pyrotinib 320mg orally once daily until disease progression or unacceptable toxicity. I.

experimental group

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Having provided written informed consent, and be able to follow clinical trial protocol.
• Men or women aged 18-75.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1，life expectancy greater than 3 months.
• Left ventricular ejection fraction (LVEF) ≥50%.
• Histopathological and/or cytological confirmed Her2-positive locally advanced or metastatic breast cancer (IHC3+, or IHC2+ and ISH+), \*ISH: Fluorescence in situ hybridization (FISH) or dual in situ hybridization (DISH); ISH positivity is defined as a ratio of HER2 gene copy number to CEP17 signal number ≥2.0. When the immunohistochemical (IHC) result is 3+, ISH testing is not required. When the IHC result is 2+, ISH testing should be performed to confirm HER2 positivity.
• Failure for at least 1 line of standard systemic treatment for metastatic disease. Meet one of the following conditions:
• Recurrent within 12 months after completing or during neoadjuvant/ adjuvant therapy (the regimens contain trastuzumab or its biosimilar with pertuzumab or not).
• Received at least one treatment with trastuzumab or its biosimilar ±pertuzumab (monotherapy or in combination with other drugs) for recurrent or metastatic disease.
• Having at least one measurable lesion according to RECIST 1.1.
• Previous exposure to taxanes.
• During the screening period and the first 7 days before treatment, the following indicators confirm appropriate organ functions:
• Hematology: WBC≥3.0×109/L；NE≥1.5×109/L；Hb≥90 g/L；Plt≥100×109/L;
• Liver function: Total bilirubin ≤ 1.5 x the upper limit of normal; AST and ALT ≤ 2.5 x the upper limit of normal, ≤ 5.0 x the upper limit of normal in the presence of liver metastases;
• Kidney function: Serum creatinine ≤1.5 x the upper limit of normal;
• Coagulation function: prothrombin time and activated partial thromboplastin time ≤1.5 x the upper limit of normal.

You may not qualify if:

• Clinical symptomatic brain metastasis is defined as untreated and symptomatic, or requiring steroid or anticonvulsant treatment to control related symptoms. Patients with asymptomatic brain metastasis, or with stable clinical symptoms and no need for steroid hormone and other treatments for brain metastasis for ≥28 days, can be enrolled.
• Have previously been treated with: another antibody-drug conjugate (ADC) consisting of DM1 or its derivative，pyrotinib and capecitabine，except for the following situations:
• During (neo)adjuvant therapy, received pyrotinib, and the participants who have experienced recurrence or metastasis more than 6 months after the last treatment and have not received pirlotinib since then are allowed to be enrolled;
• Participants who have received pirlotinib treatment during the recurrent and metastatic stage, discontinued the medication due to reasons other than disease progression, and have progressed more than 6 months after discontinuation are allowed to be enrolled;
• Participants who have received treatment with ADC drugs with different small molecule toxins (such as DS-8201, GQ1005, SHR-A1811, etc.) are eligible for enrollment. Such patients are also allowed to have received pirlotinib treatment during the recurrent or metastatic stage, and those who have progressed after more than 6 months of pirlotinib treatment are also eligible for enrollment.
• Have other malignant tumors within 5 years before signing the informed consent form ( except for cured skin basal cell carcinoma and cervical carcinoma in situ).
• Have a medical history of myocardial infarction or clinically significant heart diseases, including but not limited to,
• symptomatic congestive heart failure (CHF) (NYHA classes II-IV), or serious cardiac arrhythmia which required to therapy;
• Having a history of myocardial infarction or unstable angina pectoris within 6 months prior to the initial treatment,
• Have a corrected QT interval (QTc) prolongation to \> 450 milliseconds (ms) in males and \> 470 ms in females.
• Have clinically significant acute and chronic pulmonary diseases (e.g. interstitial lung disease (ILD), lung infection, pulmonary fibrosis, and severe radiation pneumonitis), participants with a history of ILD/non-infectious pneumonia requiring hormone therapy, or suspected of having lung diseases based on imaging examination at screening, with imaging suggesting miliary disseminated metastasis, subjects with specific pulmonary complications including but not limited to any potential lung diseases (such as pulmonary embolism, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, or other conditions that may interfere with the detection or management of drug-related pulmonary toxicity within 3 months prior to enrollment in the study), or subjects requiring oxygen therapy.
• History of allergic reaction to any component of GQ1001.
• The toxicity of previous anti-cancer therapy has not recovered to ≤1 as specified in CTCAE v5.0 (except for hair loss); e.g. chronic grade 2 toxicity might be determined per the investigator's judgment.
• The cumulative dose of anthracyclines or equivalent\>500 mg/m2.
• Uncontrollable infections require intravenous antibiotics, antiviral drugs, or antifungal drugs.

Sponsors & Collaborators

• Fudan University: lead
• GeneQuantum Healthcare (Suzhou) Co., Ltd.: collaborator

Study Sites (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China

RECRUITING

Central Study Contacts

Biyun Wang

CONTACT

18017312387; pro_wangbiyun@163.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: October 5, 2022
• First Posted: October 12, 2022
• Study Start: October 1, 2022
• Primary Completion (Estimated): December 31, 2028
• Study Completion (Estimated): December 31, 2028
• Last Updated: July 24, 2026

Record last verified: 2026-07

Locations

CN (1)